Researchers no longer need to wait four to six months or more to receive a custom antibody as they do with traditional, animal-based development methods.
Branford, Conn. (PRWEB) January 07, 2015
AxioMx Inc., a Branford, Connecticut-based biotechnology company, announced the launch of AxioMx Express, a new service featuring rapid, five-week development of affordable custom recombinant antibodies.
The AxioMx Express platform expands the range of custom recombinant antibody development options offered by AxioMx, an established leader in the field of antibody discovery. By streamlining and integrating its proprietary Rapid Liquid Screening and AxioMx Mutagenesis affinity maturation processes, AxioMx has dramatically reduced the time required for antibody development.
Tom Thompson, vice president of sales and marketing, at AxioMx, said, “Researchers no longer need to wait four to six months or more to receive a custom antibody as they do with traditional, animal-based development methods. AxioMx’s Express platform can generate custom antibodies to antigens in just over one month, helping our customers attain results and publish faster.”
This increase in speed is accompanied by an affordable price, Thompson said. “For less than $5,000, AxioMx Express delivers up to four recombinant antibodies to the customer’s antigen, and this full price is applied only if we successfully develop at least one antibody that meets our strict performance criteria.”
In addition, AxioMx’s web-based ordering process is simple, requires no quotes, and takes less than five minutes. AxioMx typically delivers recombinant antibodies in the form of human-derived scFvs, or single-chain variable fragments. These consistent, reproducible antibodies can be used in a variety of laboratory applications, such as western blotting and ELISA, and can be easily converted to an IgG format. Unlike conventional antibody generation processes, AxioMx’s methods are completely in vitro and animal-free.
About AxioMx Inc.
AxioMx, founded in 2012 and based in Branford, Connecticut, is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Michael Weiner, Ph.D., are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics, and proteomics organizations. AxioMx’s unique platform of proprietary phage display libraries, Rapid Liquid Screening, and affinity maturation methods enables the fast delivery of recombinant antibodies with high specificity, affinity, and reproducibility that are optimized to perform a desired application. The company offers a full range of custom antibody discovery and development services for the research, diagnostic, and therapeutic marketplaces. For more information about AxioMx, please visit http://www.axiomxinc.com.